- Invia ad un amico
- RSS
- google +
- Versione stampabile
- Inviare questa pagina per posta elettronica
Notizie (Medicine e trattamenti)
I feed relativi a notizie ed eventi del portale Salute-UE sono generati automaticamente sulla base di criteri forniti dalla Commissione europea. Non si escludono errori di classificazione.
Cluster meeting on the contribution of the European Union to improve transplantation and blood transfusion practices in Europe, Madrid, 27-28 June 2013 - Agenda and registration form» europa.eu
The Executive Agency for Health and Consumers implements the EU Health Programme, the Consumer Programme and the Better Training for Safer Food initiative[...]European Medicines Agency’s Management Board endorses revised EMA Code of Conduct» europa.eu
At its meeting held on 13 June 2013, the European Medicines Agency's (EMA) Management Board adopted the revised EMA Code of Conduct, which aims to ensure that the Agency maintains the highest profess[...]Registration opens for workshop on EMA-HTA parallel scientific advice in drug development» europa.eu
The European Medicines Agency (EMA) is inviting expressions of interest in attending its workshop on parallel scientific advice in drug development with health-technology-assessment (HTA) bodies on 2[...]Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 June 2013» europa.eu
The Pharmacovigilance Risk Assessment Committee (PRAC) made recommendations on four safety referrals at its June 2013 meeting.[...]PRAC recommends restricting the use of flupirtine-containing medicines» europa.eu
The European Medicines Agency?s Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of flupirtine-containing medicines and recommended restrictions in their use.[...]Are you a journalist interested in health? The EU Health Prize for Journalists 2013 has just been launched»
EU Health Prize for Journalists is awarded to stimulate high-quality journalism that raises awareness of issues related to good health, healthcare and patients' rights.
Using gene therapy to tackle complex brain disease» europa.eu
Substantial progress has been made in the development of treatments for a particular brain disease, thanks in part to an EU-funded project. The X-ALD project focused on achieving a better understandi[...]Research Headlines - Laying down markers for future cancer treatments» europa.eu
Targeting existing proteins in the human body which contribute to the growth of cancerous cells can help researchers develop tailor-made treatments. A team of EU researchers is working on ways to tri[...]Scientific guideline: Draft guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, draft: consultation open» europa.eu
This guideline lays down the non-clinical and clinical requirements for a biological medicinal product claiming to be similar to another one already marketed ([...]Revised guideline on biosimilars containing biotechnology-derived proteins published for public consultation» europa.eu
The European Medicines Agency has released a revision of the guideline addressing the clinical and non-clinical issues related to similar biological products (biosimilars) containing biotechnology-de[...]Regulatory and procedural guideline: Draft guideline on the acceptability of names for human medicinal products processed through the centralised procedure, draft: consultation open» europa.eu
The current update of this guideline provides further recommendations on the requirements for acceptability and submission of proposed (invented) names of medicinal products processed through the cen[...]Scientific guideline: Guideline on good pharmacovigilance practices (GVP): Module VI – Management and reporting of adverse reactions to medicinal products, draft: consultation open» europa.eu
This Module addresses the legal requirements detailed in Title IX of Directive 2001/83/EC [DIR] and Chapter 3 of Regulation (EC) No 726/2004 [REG], which are applicable to competent authorities in Me[...]Public consultation open on guideline on the acceptability of names for human medicines» europa.eu
The European Medicines Agency has released the sixth revision of the guideline on the acceptability of names for human medicinal products processed through the centralised procedure for public consul[...]European Medicines Agency and EUnetHTA review progress of their cooperation» europa.eu
The European Medicines Agency (EMA) and EUnetHTA, the European network for Health Technology Assessment (HTA), met to review the progress of their cooperation in London on 14 May 2013. This was the s[...]Alzheimer’s disease drugs linked to reduced risk of heart attacks » escardio.org
Drugs used for treating Alzheimer's in its early stages are linked to a reduced risk of heart attacks and death, according to a large study of over 7,000 people with the disease in Sweden published o[...]Revised version of application form for initial evaluation of human medicines available» europa.eu
The European Commission has published a revised version of the application form for all marketing-authorisation applications for medicines for human use.[...]Personalising treatments for cancer therapy» europa.eu
According to the World Health Organization (WHO), cancer is the leading cause of death worldwide, accounting for 7. 6 million deaths (around 13 % of all deaths). Despite significant efforts invested [...]Scientific guideline: Concept paper on the need for revision of the guideline on clinical investigation of medicinal products for the treatment of venous thromboembolic disease, draft: consultation open» europa.eu
Since the publication of the EMA Guidance on clinical investigation of medicinal products for the treatment of venous thromboembolic disease (CPMP/EWP/563/98) in 2000, there has been an intense resea[...]Oral almitrine to be withdrawn by EU Member States» europa.eu
The Co-ordination Group for Mutual Recognition and Decentralised Procedures ? Human (CMDh), a medicines regulatory body representing the EU Member States, has endorsed the recommendation by the Europ[...]Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013» europa.eu
This page provides an overview of the opinions adopted at the May 2013 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes.[...]Shortening the time from medical research to treatment» europa.eu
Chronic diseases such as cancer and Alzheimer's have seen an increase across Europe due to higher life expectancy and changes in lifestyle. In principle it is biomedical research that will lead to di[...]European Medicines Agency publishes guideline on clinical investigation of medicines for depression» europa.eu
The European Medicines Agency has published a guideline on clinical investigation of medicines for the treatment of depression.[...]Benefits of Diane 35 and its generics outweigh risks in certain patient groups - PRAC recommendation endorsed by CMDh» europa.eu
The Coordination Group for Mutual Recognition and Decentralised Procedures ? Human (CMDh) has endorsed by majority (26:1) the recommendation of the European Medicines Agency?s Pharmacovigilance Risk [...]Scientific guideline: Draft guideline on the clinical development of medicinal products intended for the treatment of pain, draft: consultation open» europa.eu
This document is intended to give guidance on the investigation of medicinal products to be used in the treatment of nociceptive pain and / or of central and peripheral neuropathic pain.[...]Medical Devices proposal: more than 1,000 amendments to be discussed » epha.org
More than 1,000 amendments will be discussed today (29 May) during the European Parliament's Committee on Environment, Public Health and Food Safety (ENVI) meeting on the proposals for a Medical Devi[...]Why is it important to organise a joint session with the Heart Failure Association of the ESC » escardio.org
Joint sessions provide a unique opportunity to exchange ideas and establish closer links in research, education and clinical initiatives, discuss with others, foster communications, exchange views an[...]Developing human organs and body parts in the lab» europa.eu
Tissue engineering is making a huge impact in the world of science with artificial scaffold structures, in which new cells are encouraged to grow. This means that the nanostructure of tissues in the [...]EU research making headway in early cancer detection» europa.eu
An EU-funded project is pushing the envelope on cancer treatment delivery, through the development of emerging technology based on magnetic resonance imaging (MRI) and high-intensity focused ultrasou[...]European Medicines Agency issues six key recommendations to tackle the issue of medication errors» europa.eu
The European Medicines Agency (EMA) has issued six key recommendations to tackle the issue of medication errors causing harm in the European Union (EU).[...]Public consultation on advanced therapy medicinal products» europa.eu
European Commission - A summary of the responses is here. Academic GMP Research Consortium[...]European Medicines Agency reiterates PRAC recommendation for Diane 35 and generics» europa.eu
Following the conclusion of the Pharmacovigilance Risk Assessment Committee (PRAC) that the benefits of Diane 35 and its generics outweigh the risks in a specific patient group, the French National A[...]International Clinical Trials Day: 20 May 2013» europa.eu
The European Medicines Agency supports International Clinical Trials Day, which is took place on Monday 20 May 2013.[...]Benefits of Diane 35 and generics outweigh risks in specific patient group » europa.eu
The European Medicines Agency?s Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefits of Diane 35 (cyproterone acetate 2 mg, ethinylestradiol 35 micrograms) and its gener[...]European Medicines Agency recommends first vaccine for foot-and-mouth disease for authorisation at EU level» europa.eu
The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has recommended the marketing authorisation for Aftovaxpur DOE for use in response to outbreaks of foot-and-[...]European Patients' Rights Day: 10 benefits the EU brings to patients» europa.eu
Commission MEMO Brussels, 15 May 2013 European A high level of health protection; the right to benefit from medical treatment; access to healthcare - preventive, diagnostic and curative treatment reg[...]Hospital visits take on new meaning with therapeutic robots» europa.eu
Having hospital visits from a robot may sound like a strange form of therapy, but according to robotics experts, they can be extremely helpful therapeutic devices. The idea comes from the MOnarCH pro[...][EPHA Briefing] Access to Medicines in Europe in Times of Austerity» epha.org
When discussing the topic of access to medicines in the context of the economic crisis we have to consider three determinants: affordability and availability, in terms of access to medicines, and inn[...]Commission awards prizes to best eHealth SMEs»
The winners of the 2nd EU SME eHealth Competition came up with innovations in areas such as improving cognitive behavioural therapy for mental care, improving physiological monitoring, and people facing emergencies.
New recommendations on the use of phthalates and parabens as excipients in human medicines released for public consultation» europa.eu
The European Medicines Agency has published today a draft guideline on the use of phthalates and a reflection paper on the use of parabens as excipients in human medicines, which include precautionar[...]Launch of World MS Day 2013: Raising awareness of the challenges facing young people with MS»
The campaign this year centres on asking ‘What’s your Motto?’. We all have mottos and inspirational words that get us through the tough times in life. The 2013 campaign will share the mottos of six inspiring young people for identity, relationships and the future, as well as inviting the public and people with MS to share their own mottos on the website.
European gene therapy research may restore essential human senses» europa.eu
A world without hearing, sight or smell; without music, the light of the day or the scent of a delicious meal. This is the reality for those who suffer from congenital cilia diseases, a condition ste[...]European Medicines Agency reorganisation» europa.eu
The first details of the planned reorganisation of the European Medicines Agency (EMA) have been announced.[...]Research Headlines - Sweetening the bitter pill of cancer treatment» europa.eu
Despite a massive research effort, cancer is still a major killer in Europe. European researchers are working on a sugar-based drug-delivery system which they believe will boost the potency of anti-c[...]European Medicines agency publishes final advice from clinical trial advisory groups» europa.eu
The European Medicines Agency (EMA) has published the final advice from the advisory groups that have been set up to inform the EMA in drafting its policy on proactive access to clinical-trial data.[...]RareConnect announces 40th online community»
RareConnect.org, the platform created, monitored and run by patient organisations EURORDIS and NORD, continues its mission of bringing rare disease patients together, across borders and beyond language barriers
Recommendation to suspend tetrazepam-containing medicines endorsed by CMDh » europa.eu
Following the recent recommendation by the Pharmacovigilance Risk Assessment Committee (PRAC), the Co-ordination Group for Mutual Recognition and Decentralised Procedures ? Human (CMDh) has endorsed [...]Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013 (europa.eu, ) »
This page provides an overview of the opinions adopted at the April 2013 meeting of the CHMP and other important outcomes.[...]European Medicines Agency recommends approval of combined advanced-therapy product (europa.eu, ) »
The European Medicines Agency?s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for MACI (matrix-induced autologous chondrocyte implantation), an advance[...]European Medicines Agency recommends approval of first treatment for pseudobulbar affect (europa.eu, ) »
The European Medicines Agency?s Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for Nuedexta, a medicine for the treatment of pseudobul[...]
Periodic Report Summary - CANCERALIA (Development of novel diagnostic and therapeutic approaches to improve patient outcome in lung and pancreatic tumours)»
europa.eu
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III Project context and objectives: Lung and pancreatic cancer represent major public health challenges in Europe and the western world[...]The European Medicines Agency (EMA) publishes list of drugs under additional monitoring» epha.org
As part of the deliverables of the pharmacovigilance legislation that came into effect in July 2012, the European Medicines Agency (EMA) released an initial list of drugs subject to additional monito[...]European Medicines Agency publishes initial list of medicines under additional monitoring» europa.eu
The European Medicines Agency has published today the initial list of medicines that are subject to additional monitoring.[...]New treatment may lead the way to fighting obesity and diabetes» europa.eu
Two professors believe they may have a promising lead from which to develop a new treatment for obesity and diabetes. The project titled i2MOVE ('Intelligent implantable modulator of vagus nerve func[...]Stem cell therapy treatments» europa.eu
Concerns have been raised in the media about certain stem cell therapy treatments.[...]World Immunisation week (20-27 April) – New vaccine scheduler»
A new interactive platform of vaccination schedules for individual European countries and for specific age groups has been developed by the European Centre for Disease Prevention and Control (ECDC), with the Groupe d’Etudes en Preventologie.